Identification and characterisation of antigen-specific CD8 T cells in human disease.

Pia Kvistborg

Checkpoint targeting and T-Cells

The checkpoint targeting therapies have changed the treatment of many malignancies. However, there is still a substantial part of patients who experience moderate or no benefit.

To understand how we can improve and expand treatment options for these patients we are investigating if the state of the tumor specific T cells can be further improved to control the disease in different types of cancers, what the antigenic driver of the tumor reactive T cell response is, and how we can improve the visibility of the tumors to the T cells.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.